NEW YORK (GenomeWeb) – Biomarkers predicting cancer drug response can be uncovered from omics data of patient samples as well as cell lines, according to a new study.
Investigators have previously had mixed results when trying to use cancer cell line profiling to test the function and therapeutic relevance of molecular alterations uncovered in tumor samples. According to a trio of University of California, San Francisco, researchers this, is in part due to differences between cell lines and the tumors they represent.